Red Tree Venture Capital, a West Coast-centric, early stage-biased life science venture capital firm, announced a $272m final close of its inaugural fund, Red Tree Venture Capital Fund I.
Founded in 2020 by Heath Lukatch, Ph.D. and Jennifer Cochran, Ph.D., Red Tree is a San Francisco Bay Area-based life science venture firm focused on investing in innovation emerging from premier West Coast academic and research institutions. The group leverages relationships with scientific luminaries and serial entrepreneurs at the region’s leading institutions to source opportunities focused on first-in-class and/or best-in-class therapeutics addressing significant unmet needs in the areas of oncology, neurology, and immunology.
Red Tree has already committed a portion of its new fund to investments in ten companies, each of which is at the forefront of scientific innovation within its field:
To date, Red Tree’s portfolio includes:
- Acrigen Biosciences
- Alladapt Immunotherapeutics
- Ceribell
- Excellergy Therapeutics
- Magnus Medical
- Pipeline Therapeutics
- Rondo Therapeutics
- Sardona Therapeutics
- Syncopation Life Sciences
- Virsti Therapeutics
Rounding out the Red Tree founding team is experienced drug developer Krishna Polu, M.D.
FinSMEs
06/10/2022